A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578
This study is recruiting at 14 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Gastric Adenocarcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Toray Industries, Inc
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- City of Hope · Duarte, CA
- City of Hope at Orange County Lennar Foundation Cancer Center · Irvine, CA
- University of California, Los Angeles · Santa Monica, CA
Texas · 11
- Texas Oncology Arlington North · Arlington, TX
- Texas Oncology Bedford · Bedford, TX
- Texas Oncology Dallas Medical City · Dallas, TX
- Texas Oncology Dallas Methodist · Dallas, TX
- Texas Oncology Dallas Presbyterian · Dallas, TX
- Texas Oncology Methodist Charlton Cancer Center · Dallas, TX
- Texas Oncology-Sammons Cancer Center · Dallas, TX
- Texas Oncology Fort Worth Cancer Center · Fort Worth, TX
- Texas Oncology Grapevine · Grapevine, TX
- Texas Oncology Plano East · Plano, TX
- Texas Oncology Plano West · Plano, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.